Professor Jonathan Edwards is an Emeritus Professor of Connective Tissue Medicine at University College London (UCL) in the UK. Professor Edwards was instrumental in the discovery of the use of B-cell depletion therapy (Rituximab) to treat rheumatoid arthritis.
B-cell depletion ME/CFS research[edit | edit source]
Professor Edwards became interested in the possible use of Rituximab to treat ME/CFS after attending the Invest in ME International ME Conference in May 2013 and subsequently agreed to advise on and lead the effort.
Committees and boards[edit | edit source]
Phoenix Rising[edit | edit source]
Science for ME[edit | edit source]
Advocacy[edit | edit source]
Open Letters to The Lancet[edit | edit source]
In response to The Lancet's publication of the controversial PACE trial in 2011, three open letters to the editor of The Lancet urged the editor, Richard Horton, to commission a fully independent review of the PACE trial. Dr. Edwards signed all three. The first, written in 2015, was signed by Dr. Edwards and five of his colleagues. In 2016, thirty-six additional colleagues in the ME/CFS field, signed the second letter. In 2018, a resubmitted letter had over one hundred signatories.
- Nov 13, 2015, An open letter to Dr. Richard Horton and The Lancet
- Feb 10, 2016, An open letter to The Lancet, again - Virology blog
- Jul 9, 2018, Yet Another Appeal to The Lancet, With More On Board
[edit | edit source]
- 2016, The biological challenge of myalgic encephalomyelitis/chronic fatigue syndrome: a solvable problem, Editorial by Jonathan C.W. Edwards, Simon McGrath, Adrian Baldwin, Mark Livingstone & Andrew Kewley - (Full Text)
- 2017, PACE team response shows a disregard for the principles of science in Journal of Health Psychology - (Full Text)
Talks and interviews[edit | edit source]
- May 30, 2014, Keynote Speaker at the 9th Invest in ME International ME Conference - DVD available
See also[edit | edit source]
Learn more[edit | edit source]
References[edit | edit source]
- "B cell depletion: an effective therapy in rheumatoid arthritis". www.ucl.ac.uk. Retrieved Aug 30, 2018.
- "Interview: Professor Jonathan Edwards on the UK Rituximab trial". Phoenix Rising ME / CFS Forums. Retrieved Dec 4, 2019.
- "Phoenix Rising Adds Two New Board Members". Phoenix Rising. Oct 6, 2014. Retrieved Aug 30, 2018.
- Edwards, Jonathan. "Science for ME Profile Page". s4me.info.
- Tuller, David (Nov 13, 2015). "An open letter to Dr. Richard Horton and The Lancet". Virology Blog.
- Tuller, David (Feb 10, 2016). "An open letter to The Lancet, again". Virology Blog.
- Tuller, David (Jul 10, 2018). "Trial By Error: Yet Another Appeal to The Lancet, With More On Board". Virology Blog.
- Edwards, Jonathan C.W.; McGrath, Simon; Baldwin, Adrian; Livingstone, Mark; Kewley, Andrew (Apr 2, 2016). "The biological challenge of myalgic encephalomyelitis/chronic fatigue syndrome: a solvable problem". Fatigue: Biomedicine, Health & Behavior. 4 (2): 63–69. doi:10.1080/21641846.2016.1160598. ISSN 2164-1846. PMC . PMID 27226928.
- Edwards, Jonathan Edwards (Mar 28, 2017). "PACE team response shows a disregard for the principles of science". journals.sage.pub. Journal of Health Psychology.
- "Interview: Professor Jonathan Edwards on the UK Rituximab trial". Phoenix Rising. Sep 3, 2013.
- "IIMEC9 Conference DVD". IIMEC9.
- Edwards, Jonathan (Jul 20, 2018). "Letter to Professor Watt" (PDF). meassociation.com.
Myalgic encephalomyelitis (ME) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.